Symbolbild · KI-generiert
Agios Pharmaceuticals, Inc.
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
Agios Pharmaceuticals is a biopharmaceutical company specialising in the development of medicines for rare haematological disorders. Its flagship product is Pyrukynd (mitapivat), a pyruvate kinase activator for the treatment of haemolytic anaemia.
Short profile generated automatically and checked for plausibility. A full editorial profile follows once we cover the company.
Share price
Price data from TradingView, possibly delayed. Not investment advice.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| Agios Pharmaceuticals, Inc. | AGIO | NASDAQ | 1,79 Mrd. USD |
| Damora Therapeutics, Inc. | DMRA | NASDAQ | 1,78 Mrd. USD |
| Ocular Therapeutix, Inc. | OCUL | NASDAQ | 1,79 Mrd. USD |
| Bicara Therapeutics Inc. | BCAX | NASDAQ | 1,78 Mrd. USD |
| ANI Pharmaceuticals, Inc. | ANIP | NASDAQ | 1,78 Mrd. USD |
| Lakefront Biotherapeutics | LKFT | NASDAQ | 1,79 Mrd. USD |
| Generate Biomedicines, Inc. | GENB | NASDAQ | 1,79 Mrd. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.